Company / Total Assets
PharmaCyte Biotech, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$55.2M
FY2025
5-year range
$7.4M / $90.6M
FY2021-FY2025
Trend
-7.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has declined for 3 consecutive years, from $91M in FY2022 to $55M in FY2025.
Based on SEC 10-K filings.
$55M in FY2025 with a 5-year CAGR of +55.0%.
Declined from $73M to $55M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -15.2%
- 5-Year CAGR
- +55.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- PharmaCyte Biotech, Inc.'s total assets has declined for 3 consecutive years.
- 5-year CAGR of +55.0%, indicating consistent growth.
- In FY2025, total assets decreased 7.9% year-over-year.
- Peak total assets was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $55.2M | -7.9% |
| FY2024 | $59.9M | -18.3% |
| FY2023 | $73.3M | -19.1% |
| FY2022 | $90.6M | +1124.0% |
| FY2021 | $7.4M | +20.1% |
| FY2020 | $6.2M | +6.6% |
| FY2019 | $5.8M | -9.8% |
| FY2018 | $6.4M | -26.0% |
| FY2017 | $8.7M | +21.0% |
| FY2016 | $7.2M | -23.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026